EZH2 and central nervous system cancer: Repressive marks such as H3K27me3 and H3K9me3, catalyzed by histone methyltransferases (HMTs) like EZH2, are frequently dysregulated in gliomas and pediatric brain tumors, silencing antigen-processing genes and promoting immune exclusion (41).